In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Nataliya Andreychuk, CEO of Viseven, about her personal battle with breast cancer.
Almost 30 years after it was first licensed as a treatment for breast cancer, aromatase inhibitor anastrozole has been cleared for preventive use in women at high risk of
AstraZeneca and Daiichi Sankyo’s Enhertu should not be made available via the NHS for HER2-low metastatic or unresectable breast cancer after chemotherapy, according to pr
Armed with the first phase 3 data for their TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan as a second-line treatment for breast cancer, AstraZeneca
Menarini has secured EU approval for Orserdu, the first in a new class of oral selective oestrogen receptor degrader (SERD) drugs and the first innovation in endocrine the
The combination of two HER2-targeting drugs – Seagen's oral Tukysa and Roche's intravenous antibody-drug conjugate (ADC) Kadcyla – has shown a benefit over Kadcyla alone a